# A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases

> **NCT01253564** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 24 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** RO5185426

## Key facts

- **NCT ID:** NCT01253564
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-22
- **Primary completion:** 2012-03-14
- **Final completion:** 2012-03-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253564, "A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01253564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*